The Latest Malaria News, in 60 Seconds.
A peptide derived from Bacillus bacteria stimulates the production of T cells prophylactically and therapeutically, and researchers explore the use of satellite imagery to assess the suitability of malaria vectors in different geographies.
Malaria Minute on iTunes and Spotify
The malaria parasite utilises PD1, a protein that suppresses immune responses, to ensure its survival; blocking PD1 induction is, therefore, critical to stop escalation of infection. Researchers have investigated whether LD01, a peptide derived from Bacillus bacteria, can prevent such escalation. When combined with a preventative malaria vaccine, LD01 stimulates the production of antigen-specific CD8 T cells. When used therapeutically, the use of the peptide resulted in mouse survival that was associated with fewer suppressive T cells.
Researchers have explored the use of satellite imagery and big data to assess the suitability of malaria vectors in different geographies. Built on the Google Earth Engine, the tool considers a range of environmental factors that drive vector prevalence. The researchers found that nearly 21% of Malawi is suitable for breeding based on land characteristics alone.
A Peptide-Based PD1 Antagonist Enhances T-Cell Priming and Efficacy of a Prophylactic Malaria Vaccine and Promotes Survival in a Lethal Malaria Model
Leveraging Big Data for Public Health: Mapping Malaria Vector Suitability in Malawi With Google Earth Engine
Image Credits: CDC/ Dr. Mae Melvin 
The post Peptide-Based PD1 Antagonist Stimulates T Cell Responses appeared first on The Fight Malaria Blog.